The Network for Excellence in Health Innovation on Monday announced the recipients of its 2014 Innovators in Health award, which recognizes individuals whose work reflects the spirit of NEHI and embraces the mission of improving the quality of health care and reducing costs for patients and their families.
The Council for Responsible Nutrition on Monday urged the U.S. District Court in New Jersey to hold the Federal Trade Commission to the flexible “competent and reliable scientific evidence” standard for review of dietary supplement advertising.
Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease.
Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma.
Celgene Corp. earlier this week announced that the Food and Drug Administration approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis. The drug is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis, according to the company.
AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough.